|Day's Range||6.50 - 7.00|
|52 Week Range||1.51 - 7.00|
|PE Ratio (TTM)||-3.98|
|Earnings Date||Apr 27, 2017 - May 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.73|
Positive early-stage data sends the biotech's shares up.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ImmunoGen, Inc. Here are 5 ETFs with the largest exposure to IMGN-US. Comparing the performance and risk of ImmunoGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, presented data from the ongoing Phase 1 study evaluating single agent IMGN779 in patients with relapsed or refractory adult acute myeloid leukemia whose tumors express CD33.